Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning

Journal of Neuroscience Research

Volumn 89, Issue 10, 2011, Pages 1698-1706

  Goldberg, Natalie R S ^a   Hampton, Tom ^b   Mccue, Scott ^b   Kale, Ajit ^b   Meshul, Charles K ^a,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b Mouse Specifics   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dopamine; Gait; Parkinson's disease; Progressive; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BIOLOGICAL MARKER; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CELL COUNT; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FOOT FAULT BEHAVIOR; GAIT; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; REARING; SUBSTANTIA NIGRA PARS COMPACTA; TREADMILL;

ANIMALS; BIOMECHANICS; CORPUS STRIATUM; DENERVATION; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; LAMENESS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; NEURAL PATHWAYS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 79961207552     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22699     Document Type: Article

References (54)

1. Aerts P, Van Damme R, Van Elsacker L, Duchene V. 2000. Spatio-temporal characteristics of the hind-limb cycles during voluntary bipedal and quadrupedal walking in bonobos (Pan paniscus). Am J Phys Anthropol 111: 503-517.
2. Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG. 2005. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J Neuroeng Rehab doi:10.1186/1743-0003-2-20.
3. Bezard E, Dovero S, Bioulac B, Gross CE. 1997. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci Lett 234: 47-50.
4. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. 2001. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21: 6853-6861.
5. Blin O, Ferrandez AM, Serratrice G. 1990. Quantitative analysis of gait in Parkinson patients: increased variability of stride length. J Neurol Sci 98: 91-97.
6. Blume SR, Cass DK, Tseng KY. 2009. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Exp Neurol (in press).
7. Clarke PGH. 1992. How inaccurate is the Abercrombie correction factor for cell counts? Trends Neurosci 15: 211-212.
8. Ferguson MC, Nayyar T, Deutch AY, Ansah TA. 2010. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology 59: 31-36.
9. Ferrarin M, Carpinella I, Rabuffetti M, Calabrese E, Mazzoleni P, Nemmi R. 2006. Locomotor disorders in patients at early stages of Parkinson's disease: a quantitative analysis. EMBS 28: 1224-1227.
10. Fleming SM, Zhu C, Fernagut P-O, Mehta A, DiCarlo CD, Seaman RL, Chesselet M-F. 2004. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 187: 418-429.
11. Fleming SM. 2009. Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders. Int Rev Neurobiol 89: 57-65.
12. Frenkel-Toldeo S, Giladi N, Peretz C, Herman T, Gruendlinger L, Hausdorff JM. 2005. Treadmill walking as an external pacemaker to improve gait rhythm and stability in Parkinson's disease. Movement Disord 20: 1109-1114.
13. Goldberg NRS, Haack AK, Meshul CK. 2011a. Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease. Neuroscience 172: 443-452.
14. Goldberg NRS, Haack AK, Lim NS, Janson OK, Meshul CK. 2011b. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with MPTP. Neuroscience doi:10.1016/j.neuroscience.2011.02.027.
15. Guillot TS, Asress SA, Richardson JR, Glass JD, Miller GW. 2008. Treadmill gait analysis does not detect motor deficits in animal models of Parkinson's disease or amyotrophic lateral sclerosis. J Motor Behav 40: 568-577.
16. Hampton TG, Amende I. 2010. Treadmill gait analysis characterizes gait alterations in Parkinson's disease and amyotrophic lateral sclerosis mouse models. J Motor Behav 42.
17. Hausdorff JM. 2009. Gait dynamics in Parkinson's disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling. Chaos doi:10.1063/1.3147408.
18. Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL. 1998. Gait variability and basal ganglia disorders: Stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Movement Disord 13: 428-437.
19. Hedou G, Chasserot-Golaz S, Kemmel V, Gobaille S, Roussel G, Astault J-C, Andriamampandry C, Aunis D, Maitre M. 2000. Immunohistochemical studies of the localization of neurons containing the enzyme that synthesized dopamine, GABA, or γ-hydroxybyutyrate in the rat substantia nigra and striatum. J Comp Neurol 426: 549-560.
20. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4: 257-269.
21. Kale A, Amende I, Meyer GP, Crabbe JC, Hampton TG. 2004. Ethanol's effects on gait dynamics in mice investigated by ventral plane videography. Alcohol Clin Exp Res 28: 1839-1848.
22. Kamens HM, Crabbe JC. 2007. The parallel rod floor test: a measure of ataxia in mice. Nat Protoc 2: 277-281.
23. Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker H-P, Hunot S, Hartmann A, Lehericy S, Hirsch EC, Francois C. 2010. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 120: 2745-2754.
24. Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O. 2010. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease. Brain Res 1306: 176-183.
25. Kirik D, Rosenblad C, Bjorklund A. 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277.
26. Kurtz MY, Pothakos K, Jamaluddin S, Scott-Pandorf M, Arellano C, Lau Y-S. 2007. A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty. Neurosci Lett 429: 39-42.
27. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD. 2004. Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol 187: 94-104.
28. McGeorge AJ, Faull RLM. 1989. The organization of the projection from the cerebral cortex to the striatum in the rat. Neurosci 29: 503-537.
29. Meredith GE, Kang UJ. 2006. Behavioral models of Parkinson's disease: a new look at an old problem. Movement Disord 21: 1595-1606.
30. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RCJr, Lau Y-S. 2002. Lysosomal malfunction accompanies α-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 956: 156-165.
31. Morris ME, Matyas TA, Iansek R, Summers JJ. 1996. Temporal stability of gait in Parkinson's disease. Phys Ther 76: 763-777.
32. Morris ME, Huxham F, McGinley J, Dodd K, Iansek R. 2001. The biomechanics and motor control of gait in Parkinson's disease. Clin Biomechan 16: 459-470.
33. Nair-Roberts RG, Chatelain-Badie SD, Benson E, White-Cooper H, Bolam JP, Ungless MA. 2008. Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience 152: 1024-1031.
34. Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y. 1987. MPTP-induced parkinsonian model in mice biochemistry, pharmacology and behavior. Eur Neurol 26(Suppl 1): 16-23.
35. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. 1995. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15: 3863-3875.
36. Paxinos G, Franklin KBJ, editors. 2004. The mouse brain in stereotaxic coordinates, 2nd ed. Houston: Gulf Professional Publishing.
37. Peppe A, Chiavalon C, Pasqualetti P, Crovato D, Caltagirone C. 2007. Does gait analysis quantify motor rehabilitation efficacy in Parkinson's disease patients? Gait Posture 26: 452-462.
38. Petroske E, Meredith GE, Callen S, Totterdell S, Lau Y-S. 2001. Mouse model of Parkinsonism: a comparison between subacute and chronic MPTP/probenecid treatment. Neuroscience 106: 589-601.
39. Plotnik M, Hausdorff JM. 2008. The role of rhythmicity and bilateral coordination of stepping in the pathophysiology of freezing of gait in Parkinson's disease. Movement Disord 23: 444-450.
40. Potashkin JA, Blume SR, Runkle NR. 2010. Limitations of animal models of Parkinson's disease. Parkinsons Dis article ID: 658083.
41. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. 2007. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Prod Natl Acad Sci U S A 104: 13804-13809.
42. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL. 1998. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83: 165-175.
43. Schaafsma JD, Giladi N, Balash Y, Bartels AL, GUrevich T, Hausdorff JM. 2003. Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. J Neurol Sci 212: 47-53.
44. Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR. 2009. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res 16: 127-139.
45. Sedelis M, Hoefele K, Auburger GW, Morgan S, Huston JP, Schwarting RKW. 2000. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30: 171-182.
46. Sedelis M, Schwarting RKW, Hustona JP. 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125: 109-125.
47. Smeyne RJ, Jackson-Lewis V. 2005. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134: 57-66.
48. Smolen AJ, Wright LL, Cunningham TJ. 1983. Neuron numbers in the superior cervical ganglion of the rat: a critical method of cell counting. J Neuroscitol 12: 739-750.
49. Stergiou N, Harbourne RT, Cavanaugh JT. 2006. Optimal movement variability: a new theoretical perspective for neurologic physical therapy. J Neurol Phys Ther 30: 120-129.
50. Stolze H, Kuhtz-Buschbeck JP, Drucke H, Johnk K, Illert M, Deuschl G. 2001. Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. J Neurol Neurosurg Psychiatry 70: 289-297.
51. Viaro R, Mari M, Morari M. 2010. Dual motor response to l-opda and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D2/D3 receptor blockade. Exp Neurol 223: 473-484.
52. Willis GL, Donnan GA. 1987. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 402: 269-274.
53. Wu Y, Krishnan S. 2010. Statistical analysis of gait rhythm in patients with Parkinson's disease. IEEE Transact Neural Syst Rehab Eng 18: 150-158.
54. Zhao Q, Gao J, Li W, Cai D. 2010. Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson's disease. Brain Res 1346: 224-236.